CHEK1 and Miyoshi myopathy: AZD7762, an ATP-competitive CHK1/2 inhibitor, was shown to increase the action not only of alkylating agents such as melphalan and bendamustine, but also of bortezomib, especially in TP53 mutated MM cells or those with 1q21 gains [93,94].